VCP and Factor H Inhibit Influenza A Virus Entry
Solution Overview
Problem
Current methods are inadequate for effectively preventing and treating influenza A virus (IAV) infections and modulating the entry and replication of viral and bacterial pathogens.
Innovation Solution
The use of vaccinia virus complement control protein (VCP), factor H, and complement control protein (CCP)-containing proteins as modulators to prevent and treat IAV infections by regulating the entry and replication of pathogens, specifically targeting influenza A virus, through the administration of therapeutically effective amounts of these proteins or their domains, such as CCP18-20, via intranasal, intratracheal, or sublingual routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to prevent and treat IAV infections, then treatment options are limited, but effectiveness is inadequate
Solution Approach 1:
The patent introduces complement control proteins (VCP, factor H, CCP-containing proteins) as intermediary substances that mediate between the host immune system and the influenza A virus. These proteins bind to viral glycoproteins and modulate complement activation, providing a new mechanism of action that is distinct from existing antivirals and vaccines, thereby improving effectiveness while adding versatility to treatment options.
2Reliability
If complement system activation is enhanced to fight IAV, then viral neutralisation improves, but harmful inflammatory responses may increase
Solution Approach 1:
The patent utilizes parameter changes in the complement system by introducing control proteins that selectively modulate complement activation. VCP and factor H change the activation state of complement components, enhancing viral neutralisation through C3b opsonisation while simultaneously regulating the intensity and duration of inflammatory responses, thus achieving both improved viral clearance and reduced tissue damage.
3Reliability
If VCP or factor H proteins are administered to inhibit IAV entry, then viral replication is reduced, but protein dosage and administration complexity increase
Solution Approach 1:
The patent demonstrates that VCP and factor H proteins possess multiple functions: they inhibit viral entry, reduce viral replication, modulate complement activation, and regulate inflammatory responses. This multi-functionality allows a single administration to address multiple aspects of IAV pathogenesis, potentially reducing the need for multiple different therapies and simplifying the overall treatment regimen despite the complexity of individual protein administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These proteins effectively inhibit IAV entry and replication by binding to viral glycoproteins, reducing viral load, and modulating the inflammatory response in a strain-specific manner, demonstrating potential as entry inhibitors and therapeutic agents against IAV.
Implementation Method 1
These proteins effectively inhibit IAV entry and replication by binding to viral glycoproteins
Implementation Method 2
these mechanisms include neutralisation, aggregation, opsonisation and lysis of viral particles
Data Source
AI summary
The present invention further relates to using vaccinia virus complement control protein (VCP), factor H and/or a complement control protein (CCP)-containing protein as modulator of the entry and/or replication of pathogen(s), wherein the pathogen is a virus or bacteria. The present invention further relates to a method of prevention and/or treatment of influenza A virus (IAV) infection in a subject of need thereof and to a method of modulation of the entry and/or replication of pathogen(s) in a subject of need thereof.